Docoh
Loading...

FATE Fate Therapeutics

Participants
Scott Wolchko President and Chief Executive Officer
Ed Dulac Chief Financial Officer
Bob Valamehr Chief Development Officer
Wayne Chu Senior Vice President, Clinical Development
Srikripa Devarakonda Truist Securities
Alethia Young Cantor
Michael Schmidt Guggenheim
Yigal Nochomovitz Citi
Mara Goldstein Mizuho
Matt Biegler Oppenheimer
Carolina Ibanez Ventoso Stifel
Biren Amin Jefferies
Peter Lawson Barclays
Nick Abbott Wells Fargo
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Welcome to the Fate Therapeutics Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section on Fate's Web site at fatetherapeutics.com.

As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics. yours. is floor The

Scott Wolchko

a afternoon, of Therapeutics everyone results fourth P.M. Releases. on we after Good which these for be Web can call. joining site the X:XX found issued today, Time Fate quarter Investor Eastern release and you. with for results, section thanks the us Shortly press our Thank XXXX Press financial under

the XXXX Investor for was Form of addition, XX-K the be year found December can our site on shortly filed Web XX, section thereafter our Information. under and In ended Financial

risks are any change. to or date as facts underlying obligation the they XX, statements these XX-K in the statement as These our placed of forward-looking except the made required company's in be we Fate statements update well on those forward-looking information, and made which that in only Reform SEC XXXX. year like Before statements, as materially to forward-looking with can to reflect Except such earnings call results of release Safe may I'd to speak the as of by begin, events Form and provisions Therapeutics forward-looking after SEC statements to statements was management that historical factors filings reliance the as ended cause of remind questions disclaimer statements differ statements included Private company's see the everyone should circumstances. not uncertainties the Securities the forward-looking filed and circumstances that future actual Act this close issued law, the risk December conference market the the from are for XXXX today Litigation Undue facts, on press for today. on the these responses of statements. under disclaims Please forward-looking by Harbor involve

Dan FTXXX Shoemaker, review franchises clinical we and December, the disease Dr. our of Bob for Chief Dulac, FTXXX progress call and highlight Officer; each and Chief advancement our our programs today's the Dr. Dr. tumors. that on are Officer. of shared derived development; Conference clinical Ed Chief of Senior solid Valamehr, Wayne will our and Today of Financial Ash some President our data Clinical Multiplexed discuss Scientific in plans our of next Officer; cell me Chu, our Joining Vice toward our candidates at IPS development for Engineered product wave for clinical Development we

donor significant the the Therapeutics vision off an patient of years, and Stem past therapies iPSC Engineered are Cell cell overcome induced through limitations Fate pioneered has derived unprecedented where one engineered cell and for products. Clonal several lines cell the Over therapy, multiplex Master Technology, shelf Pluripotent

we several cancer. of the have Within with months, vision in on patients made delivering this benefit for great the past strides

We have be the setting. derived demonstrated and produced, cryopreserved shelf that administered mass can NK off patients the in outpatient cells iPSC to

relapsed refractory have drive We and the shelf in including patients activity candidates disease. patient the safety shown NK our responses, complete derived with product cell off iPSC having therapeutic cells of engineered demonstrated can that responses the clinical

multiple IPS patient that have rejection schedules can treatment tolerated cells of doses through derived responses We multiple demonstrated deepen that host and evidence without and of additional consisting of NK be well can dosing. cycles

platform high engineered to enhance engineered components kind mechanism be demonstrated product our of cell IPS patients. candidates bring proprietary with IPS CDXX our multiple action to synthetic multiplexed a that we and that to NK first successfully the with with effectively in attack of that biology work and NK products FDA our cancer can poor derived receptor, antibodies. targeted can we demonstrated have have can derived functional cell these used of We of tumor product component affinity non-cleavable synergize And Fc cell the

clinical the area relapsed ahead. we we by FTXXX for we In B encouraged progress of our the X disease are look promising cell We a made refractory patients our lymphoma. from Phase in Rituximab the combination are of year areas in study by across B with have forward encouraged and reported data we December malignancies, to cell disease very interim with

a of CRS, containing following preparing and relapsed B neurotox receptor GvHD and that or CDXX of that this million patients treatments of November XX, product upon in response multiple responses that cycle. two grade clearance non to cycles FTXXX who complete response of of lymphoma Rituximab three FTXXX B achieved affinity consisting or XXX And complete currently following containing tolerated. One cell the suggest four achieve clinical interim XXXX, with and the host cut safety And doses achieved off FTXXX effectively refractory suggests There there clinical response. dose Collectively, cell second As to regimen three Dose were activity a any FTXXX have multiple data treatment achieving cohorts administered benefit. Rituximab treatment following cells FTXXX cleavable three response Tier the setting. was in cohort. refractory were The that evidence an following expansion with and most Rituximab of dose treatment was refractory patients objective is FTXXX. profile a first response on second of two in achieved dose We weekly efficacy in to with with are valuable and well no relapsed patients ongoing doses conferred the outpatient least schedule, believe two rejection. the dose on cycle regimens, there suggests the per one diffuse candidates’ of complete outpatient cycle can lymphoma, All B four recently early clinical two large mediated of who can of Rituximab been containing to be no of cycles previously an with synergize to patient are partial multiple these compelling fronts. patients evidence data including regimens. assessment patient lines has are or treatment clinical with was had complete the drive FTXXX high treated initiate of cell we at FTXXX at events escalation

DLPs, In monotherapy cell Cy/Flu are the received lympho mechanism patient most experimental was opportunities regimens we're treatment consisting targeted cell diffuse in as pretreated large cell seven study with recently FTXXX. given administration. heavily administered safety regimen achieved at review standard donor lymphoma, clinical a by administration a Ash of The of fronts. plus a dose response the case monotherapy, of antibody followed CDXX upon cycle believe regimens study patient deepening no pleased line FTXXX tumor of clinical any as response prior day for expanded CRS, administered to was following cycle NK both of provides XX our in action by signaling million of single IL-X of by FTXXX, addition, as day share course, car this had the used of patient's the a lymphoma, which study derived domain, Phase care. proprietary and few single and to ICANs investigation and a No where second therapy vignette of and case At significant treated investigator. FDA clinical of clinical currently reported administered is dose vivo We B conditioning, monoclonal of earlier considering and contains Since biology, in in X a an CDX-zeta activity. cells, grade cells were of FTXXX previously XX The metabolic a we're was size Rituximab. on resulted described XBX FTXXX, NK an who domain demonstration co-stimulatory ex activity a events NK cell and patient to Notably, a also XX B domain D this patient construct further the GvHD FTXXXs partial second first or refractory was consented our of to and optimized that active. of transmembrane for no on which FTXXX NK G decreases related a SAEs evidenced is

that and of second have the NK the profile differentiated FTXXX. or partial to again of patient's any CAR Additionally, can single On achieved encouraged safely of by with confer a may grade dose cells response without a as any at ICANs And administered a cells. clinical be T we patient GvHD deepened response and Once response cycle CRS, CAR suggesting the on patient's events compared IPS cycles cells benefit. XX. NK underscoring derived doses follow partial that are this of day last point, safety

administration, aggressive activity of following treatment. changes by significant will cancers It CAR relapse function for first and the continue served anti-tumor during for documented cells multiple administration doses NK weeks and cells best to be short dose persist FTXXX targeting. million first weeks the the believe weeks adoptively days cells, period we transferred that undergo duration including that in maximal T adoptively that patients is refractory However, in during phenotype the critical well with that the transferred can is and To of in the within treatment this FDA of current following XX-day monotherapy to with end, cycle. the submit cell coming cells protocol B multi-antigen Under combination rituximab to the days clinical and weeks escalation of a XX for as in amendment FTXXX the plan with enable and cohorts first dose protocol, the second lymphoma in we for multi-dosing ongoing to is administration. treatment of

of leukemia the have XX in Obinutuzumab clearance the cells been multi-antigen dose as we patients to upon monotherapy. targeting dose first lymphocytic Additionally, for plan million in first the monotherapy begin cohort. first cohort with And treated combination with enrollment chronic of

dose GMP leukemia disease enroll Notably, evaluate three will dose lymphoblastic in acute of pioneering to Last cancer. preparation T for plus continue successfully and first a cytokine as will cell IL-X our to We type treatment and IND three CAR clinical preparing make the IPS multi-center clinical a X an chronic to of study FTXXX. derived cells across ever indication IPS T FTXXX validation with doses B of independently fractionated types great to cell for conduct In initiate single the single lymphoma. run also FTXXX. each support development and release year, we've clear we CAR for product three testing FTXXX derived regimens of B are each completed FTXXX, continue progress we and malignancies, and the and candidate FDA initiation, now Phase product cell first lymphocytic for trial of worked leukemia, for application manufacturing

We also we Janssen process, innovate run manufacturing have second manufacturing ONO with continued implement to a FTXXX including GMP and of initiated our collaborations under improvements. to our certain and and optimize

precedent been is per We in opportunity the to treat there Most has cell at the however, potentially strong relapsed and is matched for eligibility off therapeutic cell with for enabling three to shelf refractory Dose our strong burden, have one XXX one of derived donor AML. there limited infused AML requirement patient second treatment field, single FTXXX stem patients area believe weekly product where for the conducted XXXX, our doses eliminate FTXXX therapy. where patient patients to cells cells be for donor FTXXX multiple cryopreserved with solely significantly or programs been expect delivered studies FTXXX of middle the clinical refractory single cell clinical We the a disease qualify studies, procedure XXXX. cell of ongoing NK with allogeneic site derived that that investigator the NK AML, NK with initiated and in first is for of we relapsed significantly transplant. as million NK to that patients progress a reduce are interest a leukemic of cell are significant curative therapy patient dose of use escalation is by therapy. for as can thought In that and the dose. currently fresh manufactured doses the as to and are NK made

engineered refractory to for candidate clear diagnosed and stress An in presentation receptor samples application AML a receptor caught U.S. elderly escalation and To at three the XXX components, Additionally, patients of and of AML. immunity highlighted derived treating expression strongly affinity role from with AML. as we the refractory newly per patients assessment in cell deletion promote managed designed potential the of the marrow monoclonal FC IPS therapeutic designed the that out samples IL-XX Master a CDXX CRISPR-edited trial monoclonal of ever dose mediated European and the CDXX FTXXX line FTXXX derived antibody NK X XXX NK first iPSC with patient relapsed FTXXX, for from treatment doses combination doses antibody of in bone from therapy weekly innate targeted is FDA cells which clinical we in exploit in product assessing activity our on potential ongoing relapsed is CDXX blasts third with of currently with attention fratricide indicating therapy. CDXX investigators that therapeutic FTXXX of by gene, targeted fusion showed high non-cleavable antibody leukemic which when to tested, three CDXX potential to monoclonal the XXX CDXX are daratumumab target investigation generation Dose this daratumumab to elderly with augments for sponsored Phase At our FDA XXXX, targeted in worked Minnesota and with Masonic successfully combined million meeting is Center Cancer confers weekly to approved clinical oxidative cell ADCC, with of three and cell the Clonal FTXXX hematology prevents and combination uniformly therapy. CDXX the our product a functional the The is advance our and the is of University to resistance AML. assess AML. with IND

We to initiate in mid-XXXX. expect this trial

with of therapy incorporate area our December maturation including very the myeloma is the CAR B In compelling months generate anti-tumor application our and excited over FTXXX disease functional and programs. to both about multiple the next antigen. interest clinical data cell are to FTXXX, IND cell potential four FTXXX allowed FDA third our for first targeting ever components, a we Our XX

in studies, potential. and domain a And enable is with daratumumab expression with it domains. FTXXX and combination believe in binding BCMA to and of antigen low Importantly, myeloma The for and shown has killing X Phase greater preclinical cells novel. of cells differentiated highly for holds trials binding of we targeting other includes monotherapy target to is protocol that comparison BCMA both clinical BCMA as approach best-in-class escalation, CDXX dose levels our in BCMA dual clinical

Additionally, the infusion. approach days beginning are XX our lymphoma, to of first therapeutic regimens dose protocol clinical FTXXX leveraging single multiple by investigation both includes maximize non-cleavable treatment index of dose multi CDXX high an we the in our combining the and to maximize assessment with receptor to myeloma daratumumab affinity during ADCC. we're following Similar and

NK cell effectiveness of effectively While daratumumab CDXX also which It expressed cell impair cells fratricide, induces targets death. on may myeloma multiple the induces and ADCC.

for reducing function is patients numbers of cell In therapeutic with we NK multiple initiate with myeloma potential daratumumab. addition, impaired observations the and multiple NK of further therapeutic In dose Collectively, at benefit the activity daratumumab therapy. cell and quarter, million of in cohort cells least of in potential the myeloma, lines clinical to two with weekly often expect first second enrollment doses have and preclinical maintaining FTXXX function. suggest combination patients refractory a who XXX three of failed relapsed of

the cancer six on are to the cell T Hodgkin's lymphoma, checkpoint stage tumors. ability that that who the recognize support intend address avenues the or range dose, a have Phase multiple IL-X And area cells the resistant therapeutic Since FTXXX of and million inhibitor or doses who for non-small across potential clinical pursuing XXX trial to needs tumors patient of failed We're MHC clinical NK have are investigation attacking kill treat class cells the currently lack X in which We're patients, patients presentation, investigation and administering Over NK solid refractory of with to with we benefit. cells with innate the play therapy. increase therapy. significant each to combination have antigen cancer XX X up per enthusiastic or the to our are relapsed cytokine wide we enrolling a for at classical in cells inhibitor FTXXX to directly certainly role unmet cells tumors. to unique inhibitor up We may NK evaded on believe cells next of clinical of solid relapsed. XX expansion substantially months, plan of we dose in to about checkpoint lung checkpoint

affinity combination tumors. non-cleavable FDA ADC leveraging high approved are solid promote CDXX receptor we for antibodies monoclonal to our in Additionally, with

X in enrolling competent, are combination inhibitor therapy. in cohort FTXXX We of second Phase with anti-PD-LX checkpoint dose study currently patients ADCC Avelumab, the of an our

currently our We designing settings and one and exploit programs and represents These are solid wholly-owned have FTXXX novel product with developing candidates. we undergoing under also IPS solid including cell broad program ADCC, ideal NK to believe product other development. three of programs actively targeting preclinical Janssen. CAR considering we the multiplex iPSC collaboration additional our for antibodies in And framework programs And engineered include finally, cell the NK for potential platform tumor four tumors derived with CAR tumors.

four cumulative peripheral acute transplant the undergoing four GvHD. patients scheduled second derived PROTECT that incidence graft are investigational acute available XXX, two two up by ProTmune cell of is donor primary antigen expect through MICA/B, donor NK unrelated XXXX. the of submit we an for for undergoing XX% associated XXXX, the an efficacy endpoint clinical next I to of cell matched to that our Phase with shown program quarter as CAR to of program CAR for and and endpoints generation note targeting FTXXX, IND protect blood blinded GvHD have as malignancies, ProTmune where cell FTXXX, hematologic clinical NK controlled Alpha patients a our our X want through day on to pan-tumor of proprietary transplant. targeting is grades randomized domain moment first secondary grade of Janssen. allogeneic the our During be mobilized The studies to finally, experience undisclosed data in X our antigens stress And take well trial with collaboration under double primary in

free, analysis call both That proportion that relapse plan is and patients alive relapse results. quarter chronic financial I free GvHD, XX% to to GvHD survival severe endpoint fourth XXX of at subjects achieved our statistical like Ed turn GRFS studies about efficacy clinical would the or secondary and endpoints. successfully or without independently the of year. over day second shown assess without primary where of is designed one The moderate only to to PROTECT now have by highlight

Ed Dulac

Thank you, Scott.

an the iPSC last quarter financial same incorporating our milestone our to the ONOs million on product shared domain the $XX.X Turning million from product $XX a Revenue the on ONO and Janssen a for December, development binding to we candidate and certain these year. fourth derived million in preclinical with compared CAR In package antigen T revenue pharmaceutical. to period we under expressed cell was Based for quarter XXXX results, a derived $X.X data collaborations solid with was proprietary the cancer from of preclinical tumors. elected specific current for candidate data ONO received targeting fee collaboration of continue antigen ONO. ONO,

XXXX ONO the payment United our an the at to iPSC quarter and States and headquarters. losses. XXXX reminder, and associated The Europe of were candidate of we of derived These CAR G&A $XX.X including co-develop year. headcount based profits compensation, fourth product and non-cash value all with quarter, recorded expenses recognized primarily territories co-commercialize for we employee Total facility iPSC R&D quarter an in net million $XX.X milestone the with attributable the fourth expense compensation, may Sloan million the in product and under were for up was compared achieved share $X.X cell a is to a $XX.X of the a expenses with maintains $X.X Kettering. development under we CAR compared share MSK joint As are a and develop compensation total to million non-operating be on and of to of based In of world. the candidate same based from eligible T attributable milestone expenses employee million last expenses company's Memorial fourth stock to CAR $XX currently to The with right the the in million period $XX or million the derived expense. million operating the $XX our been expenses In in arrangement cell of compensation. and retain corporate General $X.X an million product the we iPSC milestone payments to increase from quarter an are T option increase share in to event in owed administrative Research in trading payments received the last have XX% the fourth collaboration the same amounts fourth least payments no MSK. In subsequent derived certain increase $XX three share for non-cash where million candidate, share. And expenses per year. increase and ranging paid in lease based and cell compensation was to for quarter, XXXX period $XX.X T contingent to common primarily the up ONO. fair aggregate for associated owed of million were milestone the the headcount to clinical new for $XXX commercialize milestone to including values

equivalents balance does XX is stock convertible shares, X.X The of million common shares million X.X include each preferred outstanding million not convertible our the this the common shares be certain earnings income of valued questions. remeasure of from question was in shares liability of Common which will Instructions] approximately at of part and This would stock will the as cash, equity basis now recorded call Karnauskas aggregate or proceeds changes and comes the into with first January outstanding offering. under conditions. does not a non-operating offering. company aggregate [Operator ended like five stock XXXX fair common expense. the in XXXX Your and cash a our $XX.X of million XXXX on million to $XXX of public $XXX value open from the equity I our in January public quarterly quarter We investments. include currently The Robyn as the Securities. issued net fourth Truist to was line million from received stock

Srikripa Devarakonda

Thank call had in One your bandwidth include for progress. Kripa products? is potential so for Janssen, your your wholly-owned strategy with to congratulations much this especially and addition those the any for guys, taking And ONO Hey additional Robyn. what and in partnerships? that and all was you that my partnerships if question is I

Scott Wolchko

that. happy answer to Sure,

I absolutely think to well is that platform partnerships a if chose do as have partnerships increase bandwidth we we and amenable to so. have existing do the as additional we

Srikripa Devarakonda

an can plan FTXXX Great. And have Or also, you in can in for then, the to monotherapy FTXXX, like talk about AML program enroll your AML, run they the with continuing from you AML? it parallel? would start combo? you trial initiate overall to initiate need to the patients data see strategy trial you you And in be maybe before you're seems

Scott Wolchko

Sure.

vision vision, AML. start I'll long-term in long-term So

I interested of in engineered, to again, donor in of to in I Certainly, about NK responses. derived room not activity, historically, think I very improvement, strategies NK have end cells we're hematologic XX% for like for the there's XX% do any targeted non-engineered able patients significant in at malignancies. AML. day, seen targeted, we've the But way, think not drive shown been cells, have other derived express just think donor

with FTXXX respect a at of at potentially, by AML, a strategy. on were expression reasons a strategy we one to blasts targeted first leukemic And approach. combining daratumumab CDXX AML, in we EHA as doing in the to saw looking data I so now intrigued which really targeted think absolutely the that means It be would long-term with and was have the of we're

Operator

Your Young line Alethia next from comes question of from the Cantor.

Alethia Young

three the certainly the -- of so had go the been review. it benign think couple had mean, you has got the as notion couple I And deal an question just that far past kind maybe of how And regimen or months. part I be the around regimen? seemed conditioning a dosing I've times. conditioning back might lighter you version drug conditioning of to maybe of profile you've if four Thanks. of to are itself? use viable recently a of r a kind is, questions wanted with it's second considering exciting and pretty far, a it to as I do to regimen to

Scott Wolchko

the are I want address? not and in Wayne you there? are to room. same You Wayne,

Wayne Chu

question. great you for a asking. Thank That's

cellular currently the that combinations our one the for of defining fludarabine respect across to note for would therapies, clinical are regimen. tested. our is the just say sponsors and on don't schedule I but questions, are I programs the Fate of with the fundamental of all nature speak think the the and conditioning really We portfolio, are I using, I the some differences utilizing that that depending trials. cyclophosphamide and being indication should we're there doses the developing

receive So consistent of and of rounds And the precedent. worth the trying cyclophosphamide. does we're the think things trials, addressing to of Flu/Cy of I that to fludarabine probably current condition raised our the I that it's that's think slate clinical multiple one directly around question patient the fact potentially you with is understand, have what is mentioning combination tolerability a of

one newly Flu who and common Rituximab diagnosed patients For example, leukemia, are of in with is immuno regimens chemotherapy of lymphocytic with combination the more the Cy. chronic

cyclophosphamide able which But regimen. multiple so ongoing I see clinical give idea an address our to fludarabine pharmacokinetic not adjustment to ability of candidates. and product like and with support are a is feasible, whether some think Flu/Cy dose containing their to or the also being we patient not of studies the respect is to to perspective, of with profile but precedence as our there safety from to things of part tolerability dose And plan important only rounds question to

our that wed of not therapies necessarily in such can are be other understanding to combinations we're that cyclophosphamide not future ideas whether those table experiments and distant to too And not on conditioning. as We initial as address current question clinical that used study. and or fludarabine of in very to involves include also all interested the part a being hope the conditioning we are paradigm

Operator

next from line comes Schmidt of from Guggenheim. question Michael Your the

Michael Schmidt

your just than NK obviously, two pipelines this picture around point. question was is bigger expensive I actually, pipeline had CAR your I T longer strategy, cell more wondering program at be term engineered one So will NK follow portfolio Fate how think evolve? as may maybe cell-centric T the have question. And it And you my a up. CAR first that's I focus? more to opposed much

Scott Wolchko

long cells, Sure. history Obviously, a of of And we company. of to I There's cells. published can to the start with well Sloan T with technology initially, want compared probably T aware cell which head you're that, able And using that. XXXX. start honestly got NK collaborator, around IPS a I to cells on certainly develop Memorial with Sadelain. as the Michel history to our was derive quite cells gamma he and T started Kettering, say delta

been Our him are cells. T collaboration NK actually around into beta to about this advancing development exciting our was CAR derived sort cell clinical our underscore, and are patient cell the year. there's of respect also pushing are making collaborations we responses NK ONO about expressly really collaboration And But with been side pipeline I And cells. well we're nailed think, and quite collaboration XXX that and including let's of we excited really Janssen we've development T some honestly generated our that do of our results IPS involve seeing. the absolutely we would on alpha yes, hard are very with T and what excited have candidates. that quite And more with acknowledge super advanced cells.

take mature, instance, are NK is T an absolutely over would indication that pipeline on cell say a would types I aggressively. for We're cell NK our developing both cell significantly as while an we cell approach betting that that approach. not So I more

Michael Schmidt

the wondering planning you've then, And mention already I was And dosing deep cetera. the the time, first giving a over XXX, you same I paradigm, around about now specifically, that doses just escalation. good on At dose know question did thanks. Great, seen two after one you on cohort giving time only expansion you're have multiple or and talked et and responses the DLBCL. cycle

antibody wondering Will cycle this a be cohort? dosing regimen I dosing how this So be duration, you about therapy? just paradigm? chronic akin paradigm more it thinking was will fixed Or fixed or to an expansion in a the monoclonal time

Scott Wolchko

Yes.

question. great So,

part dose success. as continue of you expansion what with will is we think do I where us have see seen

paradigm not dose involve and it by Cy/Flu, at Cy/Flu, off expansion that be is there existing for treatment will a we we involves that of arm just may treatment seeing may treatments conditioning other of responses. cycles dose not paradigm FTXXX, excited the But experiment of At duration discussing it regimen time, we same the instance, we involve So involve the expansion a core that where kick may if with may likely FTXXX. are the involve with should existing includes you less were least dosing it also with Cy/Flu surprised be which will FTXXX. and are longer a

Operator

Next is Citi. from from Yigal Nochomovitz

Yigal Nochomovitz

are programs I a strategy, myeloma there for combo daratumumab broad and franchise had [indiscernible] FTXXX. obviously, myeloma two your with with on

strategy you Are the talk on regimens advance to data there? can to trials? X? development Phase combo settle about you stage your after So done one objective prepared with into later Or both combo you're is

Scott Wolchko

question. great a Yes, it's

say though ADCC guide let out Generally few with for I targeting been do mean, antibody what derived both the offers think in its we necessarily. I to encouraged aggressively FTXXX, approaching if we're therapy. we're Obviously, in have forward mean, really that potential XXX. we're I excited or patient to monoclonal side, very it's will in needs certainly both but the are to product we're data obviously guide are. by, we're development absolutely. say there even too seeing we're our to potential, and same lines that as and treatment, you may and with myeloma, of And today, going go best-in-class derived. pushing think be confidence opportunities bolstered we encouraged ft that lymphoma continue candidates. from open minded, And promote has programs of I I for still FTXXX IPS candidates early product what receptor to the of profiles FTXXX ability multi-antigen the I perspective, see very our programs play us clinic multi-targeted we're by any to or we for in our us, the donor strategy different clinical I CDXX mean, long-term I us what to to think of kind would clinical say, data have the whether significantly there's the sort is proprietary super

Yigal Nochomovitz

expressing and AML obviously therefore, you've any take then thanks. the combo that mentioned, XXX just XXX do that cluster, EHA for patients? for turning Okay, Is that you And study, assumption, to this fair is You're that to CDXX? to going data interesting. AML, CDXX the a XXX screening very the the that announced not you're going

Scott Wolchko

advance, them. biopsies assess but not able be for for CDXX That's in bone correct. to screening obviously, marrow in we'll getting We're

Yigal Nochomovitz

receptor include question Okay. non-cleavable, correct And the that this program? the that for to those are program, multiplex there CDXX two might be your is BXHX, the and engineering functionalities then is high IL-XX one the preclinical going beyond developing just that fusion? you And other CAR expectation on on the affinity

Scott Wolchko

about product Sure, unique question. are know I Bob, turn will I'll Bob to But candidate. into that over all let it answer we before Bob the features the I talk because putting

to it Let's we've what keep publicly disclosed.

Bob Valamehr

conferences we're multiple are Sure, put a components. ability we more things this in those today settings. attributes going things excited the add about year, later thanks, beyond talking what we some about program and And year Scott. to of expect going be for but to this whistles have to bells the CAR of to And obviously, tumor the further we'll very solid couple half BXHX the to added of at and second purpose add

Yigal Nochomovitz

much. very you Thank Okay.

Scott Wolchko

three solid receptor. building tumors, the say is CDXX starting already of edits in includes would FTXXX we're backbone, and which generally, the therefore, has I where off

Operator

from Your comes next of the question Mara Mizuho. line from Goldstein

Mara Goldstein

you're competitive relative how see clinical that you the what the and true view A question marketplace wondering I'm for on in the ultimately will the just today. NK programs multiple currently be on BCMA we what working to in on side landscape myeloma program the

Scott Wolchko

arguably continue least to we obviously, leading has is partnered CAR franchise patient to BCMA a myeloma today company at going Janssen, are derived. a and that's probably best-in-class think innovation And I myeloma in is who with that the the be amount that significant a space. in has of product candidate, if

very disease going do lend I myeloma, off itself in the that the shelf given the nature think to is So to treatment. landscape of

embedding of multiple it's will plasma given a that significant I do it multiple mechanisms cell relapse actions are attack including And lend there therapies. the still meaningful look duration to it's action which think going rates I therapy. mean, lend to today, are of think disease, to I if the and cells. myeloma, littered multi-pronged mechanisms you today, itself approach at within the with itself therapies, to bring to combination

try you myeloma how cure as about it's going long-term attack think to mechanisms I potentially and and you multiple it, action. think of take

that's so of derived. excited especially one -- And cell super a the with approach, we're IPS about things therapy

within those embed action modality, cell multiple therapy. of can a the mechanisms You single

Mara Goldstein

approach in you're I'd you have, wait your had to you what year, data, year sort exiting you terms said and for just till mass of Okay. releases last thinking ask like this would of to cohorts. critical that

So you it this year? how guys are thinking about

Scott Wolchko

I'll Sure, Ed that. let tackle

Ed Dulac

of We're to manageable a trying Yes. things more into consolidate disease digestible format areas.

think approach. do And what there to disease look oriented around we a biology, XXXX. ASH year to is think milestones so I similar I at us forward And in major CDXX this four to see you'll did

have in now into late summer one to get The early both dosing likely FTXXX be is and or we spring patients we where around AML. FTXXX first AML

updates combination those Shortly Rituximab, year. it we'll the FTXXX. in both programs, with some we as thereafter, we'll the well ongoing probably as from monotherapy lymphoma FTXXX have have call middle where So in revisit by for with Rituximab of combination

major where what FTXXX in expansion. tumors probably remarks well making come it'll And emphasizing prepared good we're as in The his the in be will progress an third ongoing have with there, combination we as solid quarter in around third mentioned milestone Scott FTXXX and Avelumab.

FTXXX, MICB with MICA well talk that not an plan the we as the but progress we'll and filings IND file to it's in have as making disclosed, may again around IND. program, Janssen also an We and opportunity we're about Amgen, to our also been referenced

begin the in a clinically, about fourthly we at And in with around in we'll also So FTXXX a but and patients second the clear but then hopefully innovation in around the number ASH, we terms myeloma those preclinically have have presence and the combination for quite FTXXX, then like multiple half we to and of that patients end bit to which in as solid last this of lastly, get into going with a tumors we'd quarter. of daratumumab year. of talk good IND small on good new year will third

revisit ASH focused clinically an as could to on disease use the we going we bit get lymphoma, data it additional a with on And quite into quarter or specifically, areas. So as well. fourth opportunity as

beginning, [ph] times AML. So lots the with data XXXX around of [XX] for year clinical set of mid-year

Scott Wolchko

ASH potentially at AML as well As too.

Operator

Biegler Oppenheimer. from question Next is from Matt

Matt Biegler

have through So, maybe XX I maybe I divided out Is amendment protocol XXXs just to missed this could me now on but walk in million. of over dose So you going terms there be if know dosing? the you're planned same several you infusions?

it would can XX or might color over XXX with you're doing XXX give just Now, I be and any helpful. million what doses like, guess say be let's and you three there

Scott Wolchko

Yes.

dose level where be our think cleared that multi-dosing would clear dose. the plan to I would currently on, we begin

just we're cells. cleared, let's for pick So million instance, if XX

have cells as doses where protocol XX cleared single of dose, cells a we're say each. a three it's may million million Let's we XX

Matt Biegler

That's Interesting. Cool…. okay. Oh, great.

Scott Wolchko

and Once million level. begin multi that of is, dose as of dose XXX single XXX protocols have, a say, multi XXX that dosing with mean, cleared million the pick analogy go look essentially if we I has dosing, you XXX clear protocol and as I the cells, single mean, if level XXX single that the dose level where multi it clear you the protocol single dose you at back, dose you you cells. well has that dosing, can

million XXX X do cell doses. could you So

Matt Biegler

indications subjective ASH Obviously, investigational are had a set? patient of I recruitment noticed are That after tick make any terms going the following in maybe or But Then more trials it. data therapies. sense. up a the investigator competitive of of question. pretty have in your you lot Got in interest

would any subjective have type you just, So insight be of helpful?

Scott Wolchko

that has in historically think dose with Yes. deal Part lot interest a seen derived programs. and been of therapy a I are we today our is, lot definitely of IPS we of escalation. we've cell interest in the there challenge

can we fast potentially by right how gated we're move. So

obviously, think today play to we we that can open like focused to efficient interest once to FTXXX, way, help of a we escalation yes, that that there. manage we're in up the expansion And think number dose we on broadly. more So, for there's sites up potential -- through much core dose but have significant with us get instance, open

Operator

Stifel. is question from Burnett Ben Next from

Carolina Ibanez Ventoso

the there? any might This Carolina questions. you enrolled a we of at risk patients of is color on Minnesota for look into study? thank our Ibanez provide I was Ben data taking get Burnett, clinical you Ventoso prevention the University for type when can been wondering, on high And relapsed

Scott Wolchko

initiated that. mean, Sure. respect mean, Wayne, that? I on jump an clinical take to with you data? study. it's investigator to I Obviously, I'll want do

So ASH, to we'll with earliest work on is with Minnesota clinical study prevention before study. the given at respect the data. that But though I a relapse data go not University of that program the expect ahead clinical Wayne. would

Wayne Chu

followed are undergo patients high autologous with otherwise transplant. who design, cell dose cell or from Yes. stem have by way risk study are patients the is that then therapy. initial would there With high And B and the respect patients goes are relapsed to it refractory these these their lymphoma chemotherapy, that

the is followed design transplant. to that by dose stem chemotherapy then essentially the transplant so autologous And add the and plus high following FTXXX combination take cell of study of rituximab

the relapsed prevention them historically cell transplant, know who still disease transplant. will stem have half we patients at of autologous relapse where that's following so from undergo least that comes And because

transplant. primary for to see or essentially the following relapse we of of relapse who one is so the after not are And increase endpoints the free, whether autologous study free can patients survival percentage

Carolina Ibanez Ventoso

multiple regarding got with a current in evidence setting? neurotoxicity you take or myeloma cells haven't much CRS Okay, similar the with we lymphoma, then, NK of do result it. of And seen NK

Scott Wolchko

Wayne. This is speculation. Go ahead, pure

Wayne Chu

those CDXX. or where seen neurotoxicity same nor in course, cytokine contrast, Scott particularly we of grade today, FTXXX haven't what to FTXXX, but speculation, cell release encouraged lymphoma, T. by we the pure And targeting We syndrome with other certainly therapies been think seen our been frequency CAR mentioned, in any observed and that the have product severity and don't see have T candidates, with neurotoxicity. have the as in of dated I antigen are or It's CRS CAR that we NK

worth, it's hope we're the what in programs. same that we by our myeloma for pattern to and So, see encouraged

Operator

question from Biren Jefferies. is Next Amin from

Biren Amin

that multiple patients XXX. myeloma, and you typically, think I have I with or dose the a five BCMA million I talk prior dara Can you about, two lines just like stated that with Or inclusion at is trial? about on failed in XXX guess, therapy. in least at because line seeing who combination you first cells of Maybe simply of With lines this a criteria? lines third the six we're CARs, median expecting guess, in, of just would expect more Are patients of therapy. refractory you at therapy and patients,

Scott Wolchko

Sure. Go ahead, Wayne.

Wayne Chu

Yes.

myeloma to on we therapy forth. think population to at prior than patients, but standard to to an enrolled akin has a patients we received trial, least be So, who lines But the I probably I prior begin therapies. see -- it's and not so standpoint received as From been a respect just therapy a respect such seeing with of say that patient CAR two just realistically, we proteasome inhibitor two to so we'll fair directed and T would this more what enroll on expect initially, lines have question. as with of agents, and have eligibility mean, to patients BCMA

Biren Amin

differentiation on what focus off CDX. I was just your the researchers, about, give maybe I but And steps And FTXXX? CDXs. you've July, guess, then, Gucci, versus last patient Okay, you last for in you on and that's that helpful. update particular with the there authors, a if CDXs think on month I a comment if sure maybe the T to And not that need saw paper on us seen differentiation CDXs could think versus talking in are from lead IND what about, talked up I cell think Eric cells then, I clinicaltrials.gov, challenges with Takeda Can iPSC T you achieve cells order efforts. in paper a I'm you question you cleared dosing? on Scott. was November. is, just mentioned status guess, of the earlier, design the

Scott Wolchko

Bob is head. Sure. nodding his

Bob question. let I'll the second So answer

including you're have the we question with doing in And We're really collaborations respect beta batch is, Bob the those And quality real-time, in we XXX. ONO second those Obviously, manufacturing will T we've first under and manufactured. our opportunity a there's and that to point implemented with manufacturing first obviously making getting The off run of some improvements working completed where for improvements. we discuss, Janssen. for developing testing continued out run currently that high think we're alpha improvements release product to on kicked we've cells. on process parallel

the work first And so little the continuing of patient bit the improvements do year. assessing that this in guided middle we've to we're we of a will enroll and

Bob Valamehr

Scott's T A referring up they cells to and the where communication point, follow reprogram. the took obviously nature study,

the they or take a the out setting they we TCR CAR the don't can the in track been locus, [indiscernible] manner advantage of. you So how because Michel with five with there have turns was a had and had it where even TCR with allogeneic has actually selection. to on, no they just signaling mitigate the places going on basically years signal to shortcut, we an we've And up us TCR and the they Sadelain into CAR. cell four strategy engineering. past for put T the available, temporal have gives What where a the we're had -- of need TCR though endogenous that's a coming And challenges, done they because that opportunity took over

question composition effective So and cell when persistence the have need product. you population. population CDXs, a discussed it's a single been compartment And a is highly very that complicated process. dose. for is CDXs as FTXXX CDX helper a a always about population. To a very our long-term your it's CDX It The of you

manner, are first a for we that the feel proper in product. strategy multi CDXs here So our the dose dosing

We actively the CDXs focus side, FTXXX. on are are working making on but CDXs of the

different CDX, So and basically, a CAR make timeline. that's our the CDXs carrying strategy mix in

Operator

Peter the of from question next Barclays. from comes Your Lawson line

Peter Lawson

mid What's to press going ASCO around like of that be is a of it kind get we kind release? data AML or kind is the that? The of plan year-ish,

Scott Wolchko

We'll a of did in or FTXXX conference announce continue it that part of we we press alongside it as will going part just what type we've We're the some of of event. ASH. part it at past, as at part of scientific do be We'll I will done one a the it conference, like do agenda, mean, just not to do We'll as off conference. release. a whether

Peter Lawson

hallow the buy AML? What's best NK with it XXX of and want to for there for kind cells? in par kind XXX be the of Is on approaches you

Scott Wolchko

think, they're excited have great AML, of patients people transplant. on state have honestly about they been to that generated again, a think disease complete the These the he not can been refractory really in relapsed look, I of AML. And responses have Historically, and that some don't any given I where options. in position are go their

donor therapy with limitations about scalable limitations. NK derived And really the so, cell at wasn't and the we're of certainly we given that looking talked some

And product candidate. an cell an the to so, rates come off CR, can the free shelf they XX% achieved shelf state with bridge where therapy, CRI the with to off leukemic transplant if we can patients XX% of drive in

I targeted about really yes, achieve made I long-term refractory do stand a think patients think the you say have with AML for comment if though, that's great a thinking that. option. strategies. have by, I impact start you AML, earlier, long-term, I therapeutic we will you can if can will And there's meaningful relapsed I engineered that

Peter Lawson

essentially? dosing, just be going increased on as there's repeat do And to chance an think generally, of then, think about Okay. you repeat we kind rejection of graft dosing,

Scott Wolchko

mean patient I this. XXX across we any this our every XXX,XXX, It's an interesting programs, look XXX, that at for question. I look of we we treat for mean, single

We seen Tier arise. have rejection not B cell mediated

investigating regimens. from you out of including it's it rounds And you comparing it's in to, on question, do a conditioning, alluded sort that more conditioning we're to as further will go out as something curve arise? the a Wayne of fair Cy/Flu non Now, as interested question. conditioning, It's fair further and

Peter Lawson

And we conditioning? can get from question, think do next away you my Flu/Cy

Scott Wolchko

going to short I order. think pretty we're in investigating that begin

Operator

from Fargo. Your Nick the Wells of Abbott comes next from question line

Nick Abbott

the are that about goes probably presumably, patients So Scott, I a talk on obvious in bit can fact XX but clinical protocol you trials, mean the now cells hospitalization. in of the therapy, the created hospitalization little the there's everything before I well, cells after any there FTXXX of for But related need AIE. about you just rely immediately follow get I'm have outpatient over wondering the time. the series an that treatment I would and and logistics, of up. then, bridging for patients And patients setting. Flu/Cy a know are required on or And rates given

Scott Wolchko

Wayne they but hospitalization off though, can when in patients, I are designed the the for of sort talk patient it's or administered patient, they the preparing rates, just first respect hospitalization need the are discussed short there the for to outpatient of with setting. cells bridging time, mean, the utilization a a of period are that of initially for say, given what first seen a be candidates the do about require center, of at certain seen there, will treat protocol to centers, the product where be second example, We shelf. therapy. delivered this they first time or we've strategy, very in use our obviously because sort most to never can I we've little

Wayne Chu

add I no time to instances co-bridging of therapy, the think where series a until Yes. were have received, FT that our was that to-date, bridging virtually to therapy we administering to experience cells for mean, in available. I reason buy where just patient made cumulative

exemplified most they've from they on themselves, as the cases, over. really and discussed get tie who refractory to soon their in what have, the study, was therapy, they had patients come eligible last a not agent a as are as to study, -- for we chemotherapy it their Flu/Cy as single become they So, they by earlier, get

and during as effects it's than hospitalization most effects for require the worth know conditioning, for who cells treatment which are thing some other as expected the virtually patient's to is seen of Flu/Cy is the due have to-date. they're period, profile underlying products, reminding as concerned, cases, in cell non-existent serious the think all adverse hospitalization disease, patients about the that combination. that safety attributable that things not which that's often in So And means our that that, in given is are any then, as of any -- experience hospitalized what almost one the far we cases, I well that's we from virtually to-date to events

Nick Abbott

for induction And dose of do the to them, it like going conditioning. at helpful. cohorts, you I'm early sounds going Are additional non even to relapse, in you on That's have you of or frontline to thinking some are primary and could begin exploration you're induction patients focus elderly failures, who of therapy? specific for mentioned, expansion AML, a of and least cohort as intensive where some cohorts lympho ineligible

Scott Wolchko

Yes, absolutely.

in today you'll as we start this -- it lines with dose given the are I level think, to highest profile to-date. safety and think efficacy where that therapy, the is absolutely see absolutely the will flexibility an start different most opportunity the we've at seen we in AML. of where we Certainly, and FTXXX lymphoma to give given have I

Nick Abbott

one, that to which some there Okay, this last thanks. middle batch year? mentioned complete you you And XXX. improvements you the use in second then are just for to decide Are going before the of

Scott Wolchko

batch. we've we're innovating. very said, And from in like Yes, on efficacy the first the I the seeing first I lot we're But batch. mean, comfortable with we a we're probably vivo done work of will. always actually

improvements preclinical on process make they do difference. of the preclinically We have implemented side a some and

batch. take second to the going look are a at we So

Nick Abbott

to portfolio? need -- we do not then And Okay. the and felt with assume extrapolation by that should the the NK

Scott Wolchko

a over we made were where we was With making definitely had an innovation prior we this element portfolio, process was process improvement real-time have the of patient. a patient. first that improvements time. to first in NK situation treating But the treated before There occurred the

Operator

your That you is last continue. presenters, may question

Scott Wolchko

best wishes. you Perfect. everyone call, participating in for today's Thank

Operator

today's Thank and well. call Therapeutics. for Fate support your continued and interest participation you Be all your in of

all know disconnect. may You